CIMA Sciences, LLC

🩺 Rubió Metabolomics, through our OWLiver®️ Metabolomics technology, has proudly collaborated in the groundbreaking SLIM LIVER study. Findings demonstrate that semaglutide significantly improves steatohepatitis (MASH) severity in people living with HIV (PWH). 👉 Key insights from the study: Nearly one-third of participants showed substantial improvement in MASLD severity after 24 weeks. OWLiver®️ Metabolomics algorithms successfully monitored improvements, providing non-invasive staging without liver biopsies. The SLIM LIVER study was co-funded by the ACTG network and UTHealth Houston. 📌 Poster 757 presented today at #CROI2025. #RubióMetabolomics #OWLiver #Metabolomics #HIV #ClinicalResearch #Steatohepatitis #LiverHealth

CIMA Sciences, LLC presented next with Alejo Llopart-Mascaro discussing OWLiver® which is a non-invasive test based on metabolomic technology that determines the activity of the liver through the evaluation of 28 metabolites * A reliable diagnosis of the patient in any harmful phase of MASLD. * Allows monitoring the follow-up of the patient, seeking surveillance in the regression or progression of MASH and liver fibrosis. Conclusions: * A blood-based test, so no investment required * a reliable diagnosis of the patient in any harmful phase of MASLD, not just Fibrosis * Allows monitoring the follow-up of the patient, seeking surveillance in the regression or progression of MASH and liver fibrosis * is the combination of 2 algorithms developed and validated against BIOPSY, without indeterminate zone * Good correlation with NITs in guidelines * High Sensitivity and Specificity * No impact of BMI or Statins in accuracy * Clinically available since January Arizona Liver Health American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology

The year 2024 has marked significant progress in the field of MASLD and MASH, with groundbreaking advancements in diagnostics, treatments, and clinical guidelines. Here’s a concise look at our pick for the top 10 developments that are shaping the future of liver health and patient care. American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Global NASH Council, Surfing MASH, Canadian Association for the Study of the Liver, European Association for the Study of Obesity (EASO), European Association for the Study of Diabetes e.V. (EASD), Madrigal Pharmaceuticals, Novo Nordisk, Boston Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Akero Therapeutics, Echosens, Perspectum Ltd, Aegle Medical, Mindray North America, E-Scopics, Livivos, Inc Fibronostics, Siemens Healthineers, CIMA Sciences, LLC, Predictive Health Intelligence, Inventiva Pharma, PPD, Thermo Fisher Scientific, Global Liver Institute, European Liver Patients' Association - ELPA, Medscape Education, MCI, Barcelona Institute for Global Health (ISGlobal), MASH Cities, DiaLeb - National Diabetes Organization, American Liver Foundation, American Diabetes Association, Diabetes Canada, Obesity Canada – Obésité Canada, Arizona Liver Health,Evido Health

Check out this great review article entitled “Metabolomics at the cutting edge of risk prediction of MASLD” by Dr. En Ying Tan and Dr. Mark Muthiah at National National University of Singapore, and Dr. Arun Sanyal at VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, published in Cell Reports Medicine by Cell Press this week. 📰 This carefully written review underscores the importance of metabolomics in #MASLD research as a valuable tool for the direct and real-time phenotypic characterization of this complex disease. Furthermore, the circulating metabolome reflects the systemic metabo-inflammatory milieu and the hepatic changes. 🔎 We want to highlight the overview of metabolites related to their properties, such as antioxidative, pro- or anti-inflammatory, lipotoxic or mediating proliferation, which is especially useful for the interpretation of metabolomics results. The conclusions' emphasis on MASEF score, an algorithm included in our non-invasive test OWLiver®, makes us particularly proud. As authors state, “At current, the MASEF score is the metabolomic-based biomarker demonstrating the most clinical utility as it was developed with the aim of identifying at-risk MASH, thus facilitating decision-making regarding whether an individual with MASLD would benefit from pharmacological intervention.” Thanks so much for this very interesting read!! Open access: 🔗 https://bit.ly/3DzYReU #Metabolomics #MASLD #MASH #MASEFscore #NIT

Learning about new offerings that support MASLD/MASH patients, like non-invasive biomarker assessments makes the American Association for the Study of Liver Diseases (AASLD) engaging and informative. We had the pleasure of being introduced to Alejo Llopart-Mascaro and the CIMA Sciences, LLC, OWLiver team this week. EASL the home of Hepatology, Digestive Disease Week® (DDW), Mazen Noureddin, MD, MHSc, Naim Alkhouri, MD, FAASLD, Jonathan G. Stine, MD MSc, FACP, Manal Abdelmalek, Global NASH Council, Global Liver Institute, OWL Metabolomics, European Liver Patients' Association - ELPA

Great #TLM24 Meeting so far!! Yesterday Dr. Naim Alkhouri, MD, FAASLD conclude that “#MASEF score, an algorithm in the #OWLiver test, demonstrated good correlation with the #FAST score in predicting at-risk #MASH”. Then we had a Poster of Distinction answering a question that comes when going deeper into patients Managment: #OWLiver remains robust even on patients on lipid-lowering therapy (#statins). And this afternoon, at 5pm in Ballroom 6A, the #MASEF score will be validated in the utility in the #NIMBLE project. Any additional information, find us at booth 1451 CIMA Sciences, LLC Luxor Scientific American Association for the Study of Liver Diseases (AASLD)

Join us at The Liver Meeting 2024 (#TLM2024) as we embark on the evolution of treatment for liver disease with OWLiver – the only serum-based test to identify MASLD and MASH. Together with our partners at CIMA Sciences & OWL Metabolomics, we are transforming diagnostics and helping providers determine if new prescription treatment plans are right for their patients. Stop by Booth 1451 to learn more about how OWLiver, based on the MASEF Score, could be used alternatively to LSM by VCTE.   #StepUpForLIverHealth #OWLiver #LuxorScientific #CIMASciences #Noninvasivetesting #LiverHealth #SavingLives

🔬Join us at the ADA Congress to explore our latest research on diagnosing at-risk Metabolic dysfunction-Associated SteatoHepatitis (#MASH) in Type 2 Diabetes Mellitus (#T2DM) patients. Our poster (1326-P) showcases the innovative MASEF Score as a reliable diagnostic tool. Discover how glucose levels do not significantly influence the diagnosis of at-risk MASH using the MASEF Score. 📊 Our study included 275 biopsy-proven #MASLD patients, examining the effect of glycemic control on MASH diagnosis. Key findings show that the MASEF Score and FibroScan effectively diagnose at-risk MASH regardless of glycemic control. 💡Imagine utilizing a diagnostic tool like the MASEF Score to accurately identify at-risk MASH in T2DM patients without the interference of glucose levels. Our data reveals that the MASEF Score maintains high diagnostic performance, providing clarity and precision in patient care. Be at the forefront of this diagnostic advancement. 🚀Visit our poster 1326-P at the ADA Congress, West Concourse A4-B2, on June 22, 2024, from 12:30 PM to 01:30 PM. Learn how the MASEF Score can simplify your approach to diagnosing at-risk MASH in T2DM patients. Let's advance together towards better diagnostic tools and patient outcomes! #ADACongress #MASH #MASEFScore #DiabetesResearch #ADASciSessions

At CIMA Sciences, we believe that everyone deserves access to the best healthcare technology. 🏥 That's why we're proud to offer OWLiver®, the only non-invasive test able to detect any of the damaging phases of non-alcoholic fatty liver disease (NAFLD). 🔬 OWLiver® makes it possible for patients to avoid invasive procedures and obtain accurate results. We are dedicated for advancing the field of non-invasive diagnostic technology and providing the best possible care for patients. 👩 👨🏿👨 #CIMASciences #OWLiver #NAFLD #LiverHealth #NonInvasiveTesting #Healthcare

In the News: CIMA Sciences, in partnership with Luxor Scientific, launches a revolutionary liver disease test in the US. Click the link to read about the exclusive non-invasive blood test able to detect all dangerous stages of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) – formally known as Non-Alcoholic Fatty Liver Disease – and Metabolic dysfunction-Associated Steatohepatitis (MASH). https://lnkd.in/eKD_TAjd #LuxorScientific #CIMASciences #BioSpace #MASLD #LiverDisease #MASH #AASLD #AGA #Noninvasivetesting #Bloodtesting #SavingLives